A controversy on HLA-G and B-cell malignancies?

Carosella, Edgardo D.; Rebmann, Vera

doi:10.7243/2055-2394-3-1

Cited by 1 publication

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, several studies found evidence of a relationship between HLA-G and better prognosis for B cell neoplasms [53][54]. These different observations can be attributed to the capacity of B cells to express ILT2 and therefore inhibit the proliferation of malignant B cells [55]. The fate of HLA-G interaction with its receptor on malignant B cells is determined by the balance between HLA-G-driven inhibition on these cells (as immune effector cells) and the antiproliferative effect on these cells (as target malignant cells) [55].…”

Section: Hla-g As a Target In Cancer Therapymentioning

confidence: 97%

“…These different observations can be attributed to the capacity of B cells to express ILT2 and therefore inhibit the proliferation of malignant B cells [55]. The fate of HLA-G interaction with its receptor on malignant B cells is determined by the balance between HLA-G-driven inhibition on these cells (as immune effector cells) and the antiproliferative effect on these cells (as target malignant cells) [55]. Heterogeneous patterns of HLA-G expression in different tumors may reflect differences in the biology of different types of tumor, genetic diversity among the populations studied to date, and the sensitivity of methods used to detect HLA-G [56].…”

Section: Hla-g As a Target In Cancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

HLA-G: Facts and Fictions

Shahraki

Alavianmehr

Farjadian

2018

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

Human leukocyte antigen (HLA)-G is a nonclassical MHC class I molecule with modulatory effects on NK and T cells. Unlike classical HLA class I molecules, HLA-G has seven isoforms, three of which are soluble. Soluble HLA-G molecules are reportedly able to transduce negative signals to immune cells after interacting with their corresponding receptors. The expression of these molecules plays significant roles in maternal tolerance against semi-allogenic fetuses. Overexpression of HLA-G in tumors and increased serum levels of soluble HLA-G have been reported in different malignancies, and these changes may be involved in tumoral immune evasion and cancer progression. To improve immune responses against tumor cells, the downmodulation of HLA-G by siRNA or blocking monoclonal antibodies can be helpful in cancer immunotherapy. Additionally, HLA-G can be considered a potential biomarker for the diagnosis and/or prognosis of certain cancers. Although polymorphism of the HLA-G gene-coding region is more limited than in classical HLA class I, some genetic variations in regulatory regions of the gene control the expression level of this molecule. Furthermore, epigenetic factors such as infections may affect the expression of HLA-G in infection-related cancers.

show abstract